Sarcopenia
Human evidence and active trials are visible in this field
535 human-evidence records · 43 active trials · 60 visible funding records · 7,070 universities
Australian Patent Application
Use of myostatin GDF-8 antagonists for treatment of sarcopenia age-related muscle-wasting
Source-linked patent metadata for Use of myostatin GDF-8 antagonists for treatment of sarcopenia age-related muscle-wasting, including priority, record stage and longevity-topic connections.
Australian application snapshot
Patent application record
This privacy-minimal view describes one official Australian patent application record. It is not presented as a complete worldwide patent family.
- Application number
- AU2006211813
- Earliest priority
- February 7, 2005
- Application date
- August 3, 2007
- Source record
- 1
- Patent offices
- 1
Patent-to-Evidence Translation Map
What is happening in the same scientific field?
These connections share a longevity topic with this patent record. They do not prove that the listed evidence, trials, funders, or universities validate, finance, own, or support this invention.
Why names are absent
This feed intentionally excludes party names and contact details to minimise personal data. Open the official record when a name is consequential.
Topics connected by metadata
Sarcopenia82% metadata match
How the patent office classifies this invention
A61K38/18 · A61K39/395 · A61K48/00 · A61P21/00
Verify in the original patent source →